<DOC>
	<DOCNO>NCT01311687</DOCNO>
	<brief_summary>The purpose study compare efficacy safety pomalidomide combination low-dose dexamethasone versus high-dose dexamethasone subject refractory relapse refractory multiple myeloma .</brief_summary>
	<brief_title>A Phase 3 , Multicenter , Randomized , Open-Label Study Compare Efficacy Safety Pomalidomide Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone Subjects With Refractory Multiple Myeloma Relapsed Refractory Multiple Myeloma Companion Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Must ≥ 18 year age Subjects must document diagnosis multiple myeloma measurable disease Subjects must undergo prior treatment ≥ 2 treatment line antimyeloma therapy Subjects must either refractory relapsed refractory disease define documented disease progression within 60 day complete last myeloma therapy All subject must receive least 2 consecutive cycle prior treatment include lenalidomide bortezomib All subject must fail treatment lenalidomide bortezomib one follow way : 1 ) Documented progressive disease within 60 day complete treatment lenalidomide and/or bortezomib , 2 ) In case prior response [ ≥ partial response ( PR ) ] lenalidomide bortezomib , subject must relapse within 6 month stop treatment lenalidomide and/or bortezomibcontaining regimen , 3 ) Subjects ≥ minimal response ( MR ) develop intolerance/toxicity minimum two cycle lenalidomide and/or bortezomibcontaining regimen Patients must receive adequate prior alkylator therapy Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Females childbearing potential ( FCBP ) must become pregnant 28 day prior initiation study drug , study , 28 day discontinuation Females must agree abstain breastfeed study participation 28 day study drug discontinuation Males must agree use latex condom sexual study 28 day follow discontinuation study Males must also agree refrain donate semen sperm pomalidomide 28 day discontinuation study Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/μL Platelet count &lt; 75,000/ μL subject &lt; 50 % bone marrow nucleate cell plasma cell Creatinine Clearance &lt; 45 mL/min Corrected serum calcium &gt; 14 mg/dL Hemoglobin ≤ 8 g/dL Serum glutamic oxaloacetic transaminase ( SGOT ) / aspartate aminotransferase ( AST ) Transaminase , serum glutamic pyruvic ( SGPT ) / alanine aminotransferase ( ALT ) &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0 mg/dL Previous therapy Pomalidomide Hypersensitivity thalidomide , lenalidomide , dexamethasone Resistance highdose dexamethasone use last line therapy Peripheral neuropathy ≥ Grade 2 Subjects receive allogeneic bone marrow allogeneic peripheral blood stem cell transplant Subjects planning eligible stem cell transplant Subjects one following : 1 ) Congestive heart failure , 2 ) Myocardial infarction within 12 month prior start study treatment , 3 ) Unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris Subjects receive follow within last 14 day initiation study treatment : 1 ) Plasmapheresis , 2 ) Major surgery , 3 ) Radiation therapy , 4 ) Use antimyeloma drug therapy Use investigational agent within 28 day 5 halflives ( whichever longer ) treatment Subjects condition require chronic steroid immunosuppressive treatment Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study Incidence gastrointestinal disease may significantly alter absorption pomalidomide Subjects unable unwilling undergo antithrombotic prophylactic treatment Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject sign informed consent form Pregnant breastfeeding female Known Human Immunodeficiency Virus ( HIV ) positivity active infectious hepatitis A , B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
	<keyword>Refractory Myeloma</keyword>
	<keyword>Resistant Multiple Myeloma</keyword>
	<keyword>Treatment-resistant Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Lenalidomide-resistant</keyword>
	<keyword>Bortezomib-resistant</keyword>
</DOC>